PMID- 18453738
OWN - NLM
STAT- MEDLINE
DCOM- 20090630
LR  - 20220330
IS  - 0019-509X (Print)
IS  - 0019-509X (Linking)
VI  - 45
IP  - 1
DP  - 2008 Jan-Mar
TI  - Three way translocation in a new variant of t(8;21) acute myeloid leukemia 
      involving Xp22.
PG  - 30-2
AB  - The t(8;21)(q22;q22) is one of the most frequent chromosomal abnormality 
      associated with acute myeloid leukemia (AML) M2 sub type. The additional 
      chromosomal abnormalities including structural and numerical are frequently 
      reported with the translocation, t (8;21)(q22;q22). We report a case of AML-M2 
      with t(X;8;21)(p22;q22;q22) associated with loss of Y chromosome. Using a dual 
      color fluorescence in situ hybridization (FISH) analysis with ETO and AML1 
      probes, we demonstrated an ETO/AML1 fusion signal on the derivative chromosome 8 
      and one ETO signal on derivative Chromosome Xp22. The patient did not respond to 
      therapy and follow-up of cytogenetics revealed same chromosome abnormality. 
      Hence, this three way translocation involving X chromosome might be associated 
      with poor prognosis.
FAU - Vundinti, B R
AU  - Vundinti BR
AD  - Institute of Immunohaematology (ICMR), 13th Floor, New Multistoryed Building, KEM 
      Hospital Campus, Parel, Mumbai - 400 012, Maharashtra, India. 
      vbaburao@hotmail.com
FAU - Kerketta, L
AU  - Kerketta L
FAU - Madkaikar, M
AU  - Madkaikar M
FAU - Jijina, F
AU  - Jijina F
FAU - Ghosh, K
AU  - Ghosh K
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - India
TA  - Indian J Cancer
JT  - Indian journal of cancer
JID - 0112040
RN  - 0 (AML1-ETO fusion protein, human)
RN  - 0 (Core Binding Factor Alpha 2 Subunit)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (RUNX1 Translocation Partner 1 Protein)
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Chromosome Aberrations
MH  - Chromosomes, Human, Pair 21/*genetics
MH  - Chromosomes, Human, Pair 8/*genetics
MH  - Core Binding Factor Alpha 2 Subunit/genetics
MH  - Fatal Outcome
MH  - Humans
MH  - Immunophenotyping
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Myeloid, Acute/drug therapy/*genetics
MH  - Male
MH  - Oncogene Proteins, Fusion/genetics
MH  - RUNX1 Translocation Partner 1 Protein
MH  - Translocation, Genetic
EDAT- 2008/05/06 09:00
MHDA- 2009/07/01 09:00
CRDT- 2008/05/06 09:00
PHST- 2008/05/06 09:00 [pubmed]
PHST- 2009/07/01 09:00 [medline]
PHST- 2008/05/06 09:00 [entrez]
AID - 10.4103/0019-509x.40644 [doi]
PST - ppublish
SO  - Indian J Cancer. 2008 Jan-Mar;45(1):30-2. doi: 10.4103/0019-509x.40644.